TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed Price. Currency in USD
8.12
-0.35 (-4.13%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close8.47
Open8.45
Bid0.00 x 4000
Ask8.17 x 1400
Day's Range7.95 - 8.55
52 Week Range6.07 - 15.72
Volume19,867,003
Avg. Volume22,361,242
Market Cap9.076B
Beta (5Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)-0.92
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 26, 2017
1y Target Est11.39
  • There’s scant evidence so far for chloroquine as a COVID-19 drug — but there’s already a shortage
    MarketWatch

    There’s scant evidence so far for chloroquine as a COVID-19 drug — but there’s already a shortage

    The millions of doses of chloroquine donated to the federal stockpile can now be used to treat COVID-19 patients. At the same time, pharmacists are concerned that prescribing the drug for the novel coronavirus has created shortages of the medication for patients with lupus and rheumatoid arthritis and raises questions about safety.

  • U.S. court rules for Teva in migraine patent dispute with Eli Lilly
    Reuters

    U.S. court rules for Teva in migraine patent dispute with Eli Lilly

    Teva Pharmaceutical Industries Ltd on Tuesday won a ruling from a U.S. administrative court that could help it fend off competition from Eli Lilly and Co in the market for migraine drugs. The Patent Trial and Appeal Board (PTAB) upheld the validity of three Teva patents on its migraine treatment Ajovy, rejecting arguments by Eli Lilly that they were invalid. In a separate legal action filed in 2018, Teva accused Eli Lilly's competing drug Emgality of infringing the same patents.

  • The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie
    Zacks

    The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie

    The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie

  • GuruFocus.com

    Covid-19 Could Benefit Generic Drug Companies

    Pricing is increasing for makers of copycat medicines Continue reading...

  • Coronavirus Drugs Already in the Pipeline
    Kiplinger

    Coronavirus Drugs Already in the Pipeline

    It's not just chloroquine. Other existing medicines are being brought to bear against COVID-19. We look at what drugs have promise against COVID-19, and when they will get here.

  • Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know
    Zacks

    Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know

    Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $7.90, moving +0.77% from the previous trading session.

  • Chloroquine, Hydroxychloroquine And Coronavirus: What You Should Know
    Benzinga

    Chloroquine, Hydroxychloroquine And Coronavirus: What You Should Know

    One of the difficulties facing American investors during the COVID-19 outbreak is separating fact from fiction, rumor from truth and speculation from confirmation.President Donald Trump has said repeatedly that chloroquine and hydroxychloroquine can be used to treat the novel coronavirus, leading to panic buying and a shortage for patients who are prescribed the drugs for their approved uses.Here's a look at what investors need to know about these drugs. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.What Are Chloroquine, Hydroxychloroquine? Chloroquine and hydroxychloroquine are drugs approved by the FDA to treat malaria. Hydroxychloroquine is also approved to treat lupus and rheumatoid arthritis due to its anti-inflammatory properties. Hydroxychloroquine is a derivative of chloroquine that has a similar structure but different chemical and biological properties.Studies suggest chloroquine is less toxic to humans than hydroxychloroquine.Both drugs have been in the news in recent weeks because of their alleged potential to treat COVID-19. Neither drug is approved by the FDA to treat the coronavirus, but Trump has referred to the drugs as game-changers in containing the outbreak.The CDC has said both drugs have demonstrated efficacy in treating severe acute respiratory syndrome coronaviruses based on limited data. A new study published this month in the journal Bioscience Trends found that chloroquine phosphate has produced positive results in treating COVID-19-associated pneumonia. China and several other countries are now recommending it as the treatment of choice for patients hospitalized due to COVID-19.Trump Says Drug 'Not Going To Kill Anybody'The controversy related to the use of both chloroquine and hydroxychloroquine stems from the fact that neither drug has gove through the lengthy and rigorous testing processes required to gain FDA approval for treatment of COVID-19. Trump said last week the fact both drugs are approved to treat other conditions is a positive."The nice part is it's been around for a long time, so we know that if things don't go as planned, it's not going to kill anybody," Trump said of hydroxychloroquine.The potential downside of the drugs is that the COVID-19 studies up to this point have been limited at best, and positive test results may be anecdotal. At the same time, while the CDC has said both drugs have been well-tolerated in COVID-19 patients, side effects include seizures, nausea, vomiting, deafness, vision changes and low blood pressure.In addition, ingesting too much of either drug could be deadly. Health officials in Nigeria have said three Nigerians have overdosed on chloroquine in attempts to combat COVID-19.An Arizona man died and his wife was hospitalized after the two ingested a version of chloroquine phosphate used to treat fish parasites.See Also: How Close Are Biotechs To Bringing A COVID-19 Treatment To Market?The Companies Involved New York has already begun clinical trials of chloroquine and hydroxychloroquine in treatment of COVID-19, and investors can reasonably expect any positive results to be fast tracked by the FDA. In the meantime, several drugmakers are stepping up to assist with testing and potential distribution.Bayer AG (OTC: BAYRY), Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and Novartis AG (NYSE: NVS) have pledged to donate both drugs where needed. Mylan NV (NASDAQ: MYL) and Amneal Pharmaceuticals Inc (NYSE: AMRX) have said they plan to ramp up production of hydroxychloroquine. TEVA Chart by TradingView new TradingView.widget( { "width": 680, "height": 423, "symbol": "NYSE:TEVA", "interval": "D", "timezone": "Etc/UTC", "theme": "light", "style": "1", "locale": "en", "toolbar_bg": "f1f3f6", "enable_publishing": false, "allow_symbol_change": true, "container_id": "tradingview_13f11" } ); A the same time, drugmakers Roche Holdings AG (OTC: RHHBY), Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) are among the companies that have begun testing other drugs for treatment of COVID-19.Here's a look at the percentage of bullish StockTwits messages related to each of the tickers mentioned: * Bayer: 93.8% bullish. * Teva: 97% bullish. * Novartis: 66.7% bullish. * Mylan: 96.8% bullish. * Amneal: 96.5% bullish. * Roche: 95.3% bullish. * Regeneron: 94.7% bullish. * Sanofi: 100% bullish.Benzinga's Take At this point, there is simply too much uncertainty associated with the virus, the ongoing clinical trials and the potential timeline for getting drugs to market to make any of these stocks anything more than a speculation at this point. Given the sentiment percentages, traders appear extremely bullish on all the drug companies at this point. Investors should proceed with caution.Do you agree with this take? Email feedback@benzinga.com with your thoughts.See more from Benzinga * Here's How Much Investing 0 In Allergan Stock Back In 2010 Would Be Worth Today(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Barrons.com

    Companies Plan to Boost Production of Controversial Malaria Drug as Demand Jumps

    Demand for hydroxychloroquine, the malaria drug that President Trump has touted as a treatment for Covid-19 despite limited evidence, has already begun to increase, according to a note from SVB Leerink analyst Ami Fadia.

  • Trump makes the case for chloroquine as a COVID-19 treatment, though it has not been approved by the FDA for this illness
    MarketWatch

    Trump makes the case for chloroquine as a COVID-19 treatment, though it has not been approved by the FDA for this illness

    President Donald Trump and the Food and Drug Administration commissioner appeared to exchange conflicting statements about how a decades-old antimalaria drug is being used to treat COVID-19.

  • Coronavirus update: 284,566 cases, 11,868 deaths, New York and Illinois in lockdown
    MarketWatch

    Coronavirus update: 284,566 cases, 11,868 deaths, New York and Illinois in lockdown

    The U.S. is wrapping up the first full business week feeling the brunt of the COVID-19 pandemic, with restaurants, bars, parks, retailers and workplaces shut down in many cities across the nation and three states in lockdown.

  • Good news for the stock market would be any potential treatment against the coronavirus
    MarketWatch

    Good news for the stock market would be any potential treatment against the coronavirus

    President Trump touts chloroquine, which has been controversial. Other drugs may find some success in the weeks or months ahead.

  • Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
    Zacks

    Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know

    In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $7.26, marking a +1.26% move from the previous day.

  • TheStreet.com

    Teva Donates 6 Million Tablets of Malaria Drug to Fight Coronavirus in U.S.

    Teva is donating 6 million tablets of a malaria drug to fight coronavirus in the U.S. The Israeli drugmaker plans to give those shipments to U.S. hospitals by March 31 and another 4 million within a month.

  • Teva donating 6 million doses of drug as potential COVID-19 treatment
    American City Business Journals

    Teva donating 6 million doses of drug as potential COVID-19 treatment

    The generic drug company is also ramping up production of the medicine, approved as a treatment for malaria.

  • Mylan, Teva in Focus As Chloroquine Being Tested for Coronavirus
    Zacks

    Mylan, Teva in Focus As Chloroquine Being Tested for Coronavirus

    Malaria drug, chloroquine, is being tested for the treatment of patients infected with COVID-19. Generic makers, Mylan and Teva ramp up efforts to contribute to the same.

  • Benzinga

    Benzinga Pro's Stock To Watch For Fri., Mar. 20, 2020: TEVA

    Benzinga Pro's Stocks To Watch For Friday * Teva Pharmaceutical Industries (TEVA) \- Shares spiked nearly 4% to set a morning high around $7.17 Thursday after President Trump, during the White House's daily coronavirus task force press conference, mentioned malaria treatments have shown promise on affecting a coronavirus infection. The compound which is now being targeted by health researchers is called hydroxychloroquine and is sold by Teva (among other producers including Bayer) under the brand name Plaquenil. Trump went on to suggest the U.S. has ordered "a lot" of chloroquine. Later Thursday, Teva issued a press release disclosing it has donated 6 million doses of hydroxychloroquine sulfate to hospitals around the U.S. Teva shares closed Thursday's session up 7% and were up another 14% in pre-market action Friday.See more from Benzinga * Benzinga Pro's Top 5 Stocks To Watch For Thurs., Mar. 19, 2020: GE, PCG, HRC, UTI, ECL * Benzinga Pro's Top 5 Stocks To Watch For Wed., Mar. 18, 2020: GIS, TSLA, BYND, ARMK, APRN * Benzinga Pro's Top 5 Stocks To Watch For Tues., Mar. 17, 2020: VOO, BNTX, PLCE, MDT, NIO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • MarketWatch

    Teva to donate 6 million doses of hydroxychloroquine, floated as a potential treatment for COVID-19

    Shares of Teva Pharmaceutical Industries Ltd. gained 13% in premarket trading on Friday following a Thursday night announcement that the drugmaker will donate more than 6 million doses of hydroxychloroquine sulfate tablets in the U.S. this month. Chloroquine, a longtime malaria drug that is sometimes used as a treatment for rheumatoid arthritis, is being floated as a potential treatment for people sickened by the novel coronavirus by the Trump administration. Teva said in a news release that the drug, which has not received Food and Drug Administration approval as a treatment for COVID-19, has been requested by government officials in efforts to treat the disease. Bayer AG and Mylan have also said they will produce chloroquine therapies as a result of the COVID-19 pandemic. Teva's stock is down 29.9% year-to-date, while the S&P 500 has dropped 25.4%.

  • Business Wire

    Teva to Donate Potential COVID-19 Treatment, Hydroxychloroquine Sulfate Tablets to Hospitals Nationwide

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the immediate donation of more than 6 million doses of hydroxychloroquine sulfate tablets through wholesalers to hospitals across the U.S. to meet the urgent demand for the medicine as an investigational target to treat COVID-19. The company is also looking at additional ways to address the global need.

  • Here is What Hedge Funds Think About Teva Pharmaceutical Industries (TEVA)
    Insider Monkey

    Here is What Hedge Funds Think About Teva Pharmaceutical Industries (TEVA)

    Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]

  • Business Wire

    Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA® (trastuzumab-pkrb) for Injection

    Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Celltrion Healthcare, Co., Ltd. (KRX KOSDAQ:091990), today announced that HERZUMA®1 (trastuzumab-pkrb) for Injection, a biosimilar to HERCEPTIN®1, is now available in the United States with the same indications as the reference product including:

  • Business Wire

    Positive Recommendation by NICE for first anti-CGRP migraine therapy: AJOVY®▼ (fremanezumab)

    Teva Pharmaceutical Europe BV an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the National Institute for Health and Care Excellence (NICE) has recommended AJOVY (fremanezumab) in its Final Appraisal Document (FAD) for the prevention of migraine in adults with chronic migraine. NICE recommends AJOVY® for chronic migraine patients who have not responded to at least three prior preventive drug treatments.

  • Reuters

    Closely watched opioid trial in New York postponed due to coronavirus

    A highly anticipated trial pitting New York state against McKesson Corp, Johnson & Johnson , CVS Health Corp and others for allegedly fueling the opioid epidemic has been postponed due to the coronavirus outbreak, according to the court. The postponement of the March 20 jury trial was a precautionary measure due to the number of people traveling to attend, according to a spokesman for New York Attorney General Letitia James. A new trial was not set but a hearing will be held April 14 to decide next steps in the case, which is in state court in Suffolk County on New York's Long Island.

  • Barrons.com

    Indian Authorities Cut Some Drug Exports

    The move was a further signal of the enormous disruption that the outbreak of the new coronavirus is having on the drug supply chain.

  • Reuters

    CORRECTED-Roche pushes to kick-start lung therapy Esbriet after big writedown

    Roche has won U.S. breakthrough therapy status for Esbriet for unclassifiable interstitial lung disease (uILD), the company said on Tuesday, as it aims to lift disappointing revenue by expanding conditions for which it can be used. Esbriet, approved in 2011 in Europe and 2014 in the United States, is now used to treat adults with lung-scarring idiopathic pulmonary fibrosis, which belongs to so-called interstitial lung disease (ILD).